A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...